The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.j

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

Publications

Lazzeroni M, Kemp P, Fokkens WJ, Reitsma S

Eosinophilic complications during dupilumab therapy for type 2 diseases: a systematic review.

Rhinology 2025 Aug 01;63 — 2025 Aug 01 — 386-396

Kai M, Vion PA, Boussouar S, Cacoub P, Saadoun D, Le Joncour A

Eosinophilic granulomatosis polyangiitis (EGPA) complicated with periaortitis, precipitating role of dupilumab? A case report a review of the literature.

RMD open 2023 Sep;9; — 2023 Sep

Suzaki I, Tanaka A, Yanai R, Maruyama Y, Kamimura S, Hirano K, Kobayashi H

Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report.

BMC pulmonary medicine 2023 Apr 19;23;130 — 2023 Apr 19 — 130